Recruiting Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC NCT07197580 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +23 more Locations Westmead Hospital — Sydney, New South Wales, Australia Wollongong Hospital — Wollongong, New South Wales, Australia Austin Health — Heidelberg, Victoria, Australia Melbourne Theranostic Innovation Centre (MTIC) — Melbourne N., Victoria, Australia View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) NCT03634540 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more Locations USC Norris Comprehensive Cancer Center ( Site 0060) — Los Angeles, California, United States Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) — Los Angeles, California, United States Sylvester Comprehensive Cancer Center ( Site 0023) — Miami, Florida, United States Dana Farber Cancer Center ( Site 0006) — Boston, Massachusetts, United States View more locations Show fewer locations Loading locations... View Trial Details
